Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10722386 | 1.00 | CHRM5 (0.43) | CHRM5ADRA2CCHRM2CHRM4CHRM1 | |
| SCHEMBL4586403 | 1.00 | CHRM5 (0.43) | CHRM5ADRA2CCHRM2CHRM4CHRM1 | |
| SCHEMBL11537690 | 0.98 | CHRM5 (0.40) | CHRM5ADRA2CCHRM2CHRM4CHRM1 | |
| SCHEMBL10563375 | 0.98 | CHRM5 (0.40) | CHRM5ADRA2CCHRM2CHRM4CHRM1 | |
| SCHEMBL3544392 | 0.92 | HTT (0.33) | CHRM5ADRA2CGBA1 | |
| SCHEMBL3934463 | 0.92 | HTT (0.33) | CHRM5ADRA2CGBA1 | |
| SCHEMBL7026183 | 0.92 | HTT (0.33) | CHRM5ADRA2CGBA1 | |
| SCHEMBL7022671 | 0.90 | CHRM5 (0.40) | CHRM5ADRA2CCHRM2CHRM4CHRM1 | |
| SCHEMBL10569368 | 0.81 | SIGMAR1 (0.38) | CHRM5ADRA2CSIGMAR1MEN1KMT2A | |
| SCHEMBL9893069 | 0.80 | CHRM5 (0.43) | CHRM5ADRA2CCHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100247540-A1 | Methods and Compositions For Modulating Angiogenesis | CHEMOCENTRYX, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100247540-A1 | Methods and Compositions For Modulating Angiogenesis | CHEMOCENTRYX, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100247540-A1 | Methods and Compositions For Modulating Angiogenesis | CHEMOCENTRYX, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100144720-A1 | INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7649011-B2 | Active against cancer proliferation, growth, and metastasis; such as 3,4,5-trimethoxy-n-(2-methyl-3-phenyl-allyl)-n-[2-(1-methyl-pyrrolidin-2-yl)-thyl]-benzamide; side effect reduction | CHEMOCENTRYX, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7417062-B2 | e.g. N (S)-(1-Cyclohexylmethyl-pyrrolidine-2-ylmethyl)-3,4-dimethoxy-N-naphthalen-2-ylmethyl-benzamide; inhibit the binding of the SDF-1 (CXCL12) chemokine or I-TAC (CXCL11) to the chemokine receptor CCXCKR2; anticarcinogenic agent; breast, lymph nodes, bone marrow, and lungs cancer | CHEMOCENTRYX, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417062-B2 | e.g. N (S)-(1-Cyclohexylmethyl-pyrrolidine-2-ylmethyl)-3,4-dimethoxy-N-naphthalen-2-ylmethyl-benzamide; inhibit the binding of the SDF-1 (CXCL12) chemokine or I-TAC (CXCL11) to the chemokine receptor CCXCKR2; anticarcinogenic agent; breast, lymph nodes, bone marrow, and lungs cancer | CHEMOCENTRYX, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417062-B2 | e.g. N (S)-(1-Cyclohexylmethyl-pyrrolidine-2-ylmethyl)-3,4-dimethoxy-N-naphthalen-2-ylmethyl-benzamide; inhibit the binding of the SDF-1 (CXCL12) chemokine or I-TAC (CXCL11) to the chemokine receptor CCXCKR2; anticarcinogenic agent; breast, lymph nodes, bone marrow, and lungs cancer | CHEMOCENTRYX, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1715892-A4 | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS | CHEMOCENTRYX INC (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1715892-A2 | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS | ChemoCentryx Inc (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2006038989-A1 | SUBSTITUTED ARYLAMIDES | CHEMOCENTRYX, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074071-A1 | Substituted arylamides | CHEMOCENTRYX, INC. (US) | 2006-04-06 | — | — | US | disclosed |
| US-20050214287-A1 | Methods and compositions for modulating angiogenesis | CHEMOCENTRYX, INC. (US) | 2005-09-29 | — | — | US | disclosed |
| WO-2005074645-A2 | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS | CHEMOCENTRYX, INC. (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074071-A1 | Substituted arylamides | AADAC, BRDT, BRPF3 | CHRM5 4857/4885ADRA2C 2849/4885CHRM2 4861/4885 |
| US-20050214287-A1 | Methods and compositions for modulating angiogenesis | VEGFA, FLT4, PGF | CHRM5 3466/4885ADRA2C 2435/4885CHRM2 3983/4885 |
| US-20100144720-A1 | INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2 | CCL2, CCR2, CXCR2 | CHRM5 4181/4885ADRA2C 1003/4885CHRM2 3407/4885 |
| US-20100247540-A1 | Methods and Compositions For Modulating Angiogenesis | VEGFA, FLT4, PGF | CHRM5 3466/4885ADRA2C 2435/4885CHRM2 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.